Targeting drugs to combinations of receptors: A modeling analysis of potential specificity

被引:50
作者
Caplan, MR [1 ]
Rosca, EV [1 ]
机构
[1] Arizona State Univ, Harrington Dept Bioengn, Tempe, AZ 85287 USA
关键词
mathematical model; multivalent; biomaterial; drug delivery;
D O I
10.1007/s10439-005-5779-1
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Targeting drugs to specific cells by conjugating the drug to an antibody or ligand for a cell surface receptor currently requires that the receptor be uniquely over-expressed by the target cell (the target cell over-expresses a particular receptor in comparison with untargeted cells, which do display this receptor type but a lesser number of them). Here we develop a mathematical model to predict the behavior of multivalent ligand-drug constructs containing two different ligands for two different receptors, which would allow targeting cells that do not uniquely over-express any receptor. In this model, target cells express both receptors at a high level; whereas, untargeted cells express one receptor type at the high level but the other at a lower level. The model predicts that these heterovalent conjugates (containing two different types of ligands) can achieve specificity even when the target cell does not uniquely over-express any one receptor type. Using the current approach, constructs in which only one ligand type is used will bind as much to untargeted cells as to the target cells. Therefore, this combination strategy can enormously expand the number of applications for which cell surface receptor targeting of drugs is an appropriate option.
引用
收藏
页码:1113 / 1124
页数:12
相关论文
共 23 条
[1]   Prognostic relevance of gene amplifications and coamplifications in breast cancer [J].
Al-Kuraya, K ;
Schraml, P ;
Torhorst, J ;
Tapia, C ;
Zaharieva, B ;
Novotny, H ;
Spichtin, H ;
Maurer, R ;
Mirlacher, M ;
Köchli, O ;
Zuber, M ;
Dieterich, H ;
Mross, F ;
Wilber, K ;
Simon, R ;
Sauter, G .
CANCER RESEARCH, 2004, 64 (23) :8534-8540
[2]  
[Anonymous], THEORETICAL IMMUNO 1
[3]   Design of a multivalent galactoside ligand for selective targeting of HPMA copolymer-doxorubicin conjugates to human colon cancer cells [J].
David, A ;
Kopecková, P ;
Minko, T ;
Rubinstein, A ;
Kopecek, J .
EUROPEAN JOURNAL OF CANCER, 2004, 40 (01) :148-157
[4]   Expression-driven reverse engineering of targeted imaging and therapeutic agents [J].
Gillies, RJ ;
Hruby, VJ .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2003, 7 (02) :137-139
[5]  
HANDL HL, EXPERT OPIN THERAP T, V8, P565
[6]   Steric effects on multivalent ligand-receptor binding: Exclusion of ligand sites by bound cell surface receptors [J].
Hlavacek, WS ;
Posner, RG ;
Perelson, AS .
BIOPHYSICAL JOURNAL, 1999, 76 (06) :3031-3043
[7]   Principles for multivalent ligand design [J].
Kiessling, LL ;
Strong, LE ;
Gestwicki, JE .
ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 35, 2000, 35 :321-330
[8]   Spanning binding sites on allosteric proteins with polymer-linked ligand dimers [J].
Kramer, RH ;
Karpen, JW .
NATURE, 1998, 395 (6703) :710-713
[9]  
Linderman J, 1993, RECEPTORS MODELS BIN
[10]  
MACKEN CA, 1985, BRANCHING PROCESSES